Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Lpcn | History Defined

Looking for a Value Investment? Check out These 3 Pharma Stocks

The pharmaceutical industry looks well-positioned for long-term growth. Therefore, fundamentally strong Merck & Co (MRK), Pfizer (PFE), and Lipocine (LPCN) could be ideal value investments now. Keep reading.

StockNews.com · Aug 17, 2023

Lipocine Posts Encouraging Data For Testosterone Prodrug In NASH Patients

Lipocine Inc (NASDAQ:LPCN) has announced topline results from its Open-Label Extension (OLE) study of LPCN 1144, including an orally delivered prodrug of testosterone. Twenty-five subjects were enrolled, of whom 16 subjects from the LiFT study continued LPCN 1144 treatment for additional 36 weeks (total of 72 weeks), and nine subjects initiated LPCN 1144…

Benzinga · May 12, 2022

LPCN: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga · May 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Top Stocks Trading Under $2

The stock market has been under pressure since the beginning of the year due to multi-decade high inflation, the potential for aggressive Federal Reserve interest rate hikes, and Russia’s invasion of Ukraine. But with peace talks between Russia and Ukraine underway, the volatility in the markets is expected to decline.…

StockNews.com · Mar 31, 2022

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

Antares Pharma Inc (NASDAQ:ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of endogenous testosterone or hypogonadism. The first time the Company got a testosterone product approved by…

Benzinga · Mar 29, 2022

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga · Mar 11, 2022

Coverage From

People

Dipanjan BanchurSince

722 stories

John Vandermosten

46 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Rave Restaurant Group Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.